

Irritable bowel syndrome - Pipeline Insight, 2021

<https://marketpublishers.com/r/IE807C42BC85EN.html>

Date: May 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: IE807C42BC85EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Irritable bowel syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Irritable bowel syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Irritable bowel syndrome Understanding

Irritable bowel syndrome: Overview

Irritable bowel syndrome (IBS) is a group of symptoms that occur together, including repeated pain in your abdomen and changes in your bowel movements, which may be diarrhea, constipation, or both. With IBS, you have these symptoms without any visible signs of damage or disease in your digestive tract. The most common symptoms of irritable bowel syndrome (IBS) are pain in your abdomen, often related to your bowel movements, and changes in your bowel movements. These changes may be diarrhea, constipation, or both, depending on what type of IBS you have. To diagnose irritable bowel syndrome (IBS), doctors review the symptoms and the medical and family history and perform a physical exam. The doctor will look for a certain pattern in the symptoms. In some cases, doctors may order tests to rule out other health problems.

'Irritable bowel syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Irritable bowel syndrome pipeline landscape is provided which includes the disease overview and Irritable bowel syndrome treatment guidelines. The assessment part of the report embraces, in depth Irritable bowel syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Irritable bowel syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Irritable bowel syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Irritable bowel syndrome.

Irritable bowel syndrome Emerging Drugs Chapters

This segment of the Irritable bowel syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Irritable bowel syndrome Emerging Drugs

Olorinab: Arena Pharmaceuticals

Olorinab (APD371) is an oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2). Olorinab is an internally discovered investigational drug candidate that Arena is exploring for development in several indications, with an initial focus on visceral pain in gastrointestinal disorders. This compound, through its selectivity for CB2, versus the cannabinoid receptor 1 (CB1), was designed to provide pain relief while minimizing the risk of psychoactive adverse effects. The drug is

currently in phase 2 of clinical trials for the treatment of irritable bowel syndrome.

Blautix: 4D Pharma

Blautix® is a single strain Live Biotherapeutic product (LBP), being developed as a treatment for both IBS-C and IBS-D. Pre-clinical studies demonstrated its ability to address visceral hypersensitivity and other symptoms of IBS and increase microbiome diversity. A Phase I study in healthy volunteers and IBS patients showed that Blautix® was well tolerated and an improvement in symptoms was also reported relative to placebo. The Phase II BHT-II-002 trial demonstrated an impact on overall response with regards to bowel habit and abdominal pain in IBS-C and IBS-D. Blautix® was well tolerated, with a safety profile comparable to placebo.

Further product details are provided in the report

Irritable bowel syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Irritable bowel syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Irritable bowel syndrome

There are approx. 24+ key companies which are developing the therapies for Irritable bowel syndrome. The companies which have their Irritable bowel syndrome drug candidates in the most advanced stage, i.e. phase II include Arena Pharmaceuticals.

Phases

DelveInsight's report covers around 24+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Irritable bowel syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Irritable bowel syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Irritable bowel syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Irritable bowel syndrome drugs.

Irritable bowel syndrome Report Insights

- Irritable bowel syndrome Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Irritable bowel syndrome Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Irritable bowel syndrome drugs?

How many Irritable bowel syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Irritable bowel syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Irritable bowel syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Irritable bowel syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Arena Pharmaceuticals

4D Pharma

OrphoMed

Boston Pharmaceuticals

RedHill Biopharma Limited

Takeda

Cosmo Technologies

CinRx Pharma

Rottapharm

SK biopharmaceuticals

Synthetic Biologics

Biomica

Dong-A ST Co Ltd

Metacrine

MGC Pharma

Napo Pharmaceuticals

Nobilis Therapeutics

Novome Biotechnologies

RQ-00310941

Renexxion

Sentia Medical Sciences

Serentrix LLC

Velicept Therapeutics

Vitality Biopharma

Oxford Cannabinoid Technologies

Key Products

Olorinab

Blautix

ORP-101

BOS-589

BEKINDA

Mesalamine

Rifamycin controlled-release

CIN 103

Dexloxiglumide

Relenopride

Lovastatin modified release

BMC426

DA-6886

MET409

Crofelemer

NBTX-001

RQ-00310941

Ser-224

Velicept

VBX-100

AAT 730

Contents

Introduction

Executive Summary

Irritable bowel syndrome: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Irritable bowel syndrome – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Irritable bowel syndrome companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Irritable bowel syndrome Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Olorinab: Arena Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

MET409: Metacrine

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Irritable bowel syndrome Key Companies

Irritable bowel syndrome Key Products

Irritable bowel syndrome- Unmet Needs

Irritable bowel syndrome- Market Drivers and Barriers

Irritable bowel syndrome- Future Perspectives and Conclusion

Irritable bowel syndrome Analyst Views

Irritable bowel syndrome Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Irritable bowel syndrome

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Irritable bowel syndrome

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Irritable bowel syndrome - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/IE807C42BC85EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IE807C42BC85EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970